Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study.

NCT02704767 is registered in ClinicalTrials.gov with First Affiliated Hospital of Kunming Medical University as lead sponsor.

NCT NCT02704767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02704767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study.
Lead sponsor
First Affiliated Hospital of Kunming Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2016
Completion date
December 31, 2019
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer